Menjugate

N. meningitidis group C (strain C11) oligosaccharide conjugated to Corynebacterium diphtheriae CRM197, the active ingredient in Menjugate, is a vaccine presented as an injectable solution for intramuscular use. It protects against invasive disease caused by Neisseria meningitidis group C in individuals at risk.

GNH USA supplies Menjugate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Menjugate is a conjugate vaccine that targets the polysaccharide capsule of Neisseria meningitidis group C to prevent meningococcal disease. - Meningococcal group C disease: provides active immunity to prevent invasive meningococcal disease caused by Neisseria meningitidis group C. - Outbreak control: helps limit the spread of group C meningococcal infections during community outbreaks. - Travel to endemic areas: reduces the risk of acquiring group C meningococcal disease for travelers to regions with known circulation.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache: mild headache within 24 hours. - Fatigue: temporary tiredness. - Myalgia: muscle aches.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypotension: sudden drop in blood pressure post‑vaccination. - Seizures: rare neurologic events. - Guillain‑Barré syndrome: extremely rare autoimmune neuropathy. - Severe local reaction: extensive necrosis or ulceration at injection site.

Before administering Menjugate, consider the following precautions: - Screen for hypersensitivity: avoid in persons with known allergy to any vaccine component. - Delay vaccination: postpone if the individual has an acute moderate or severe illness. - Pregnancy: use only when the benefit outweighs potential risk, as safety data are limited. - Concurrent vaccines: can be co‑administered according to national immunisation schedules. - Immunocompromised patients: vaccine response may be reduced; assess need for booster doses. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other agents that affect the immune system. Major Interactions (Avoid): - Live bacterial vaccines (e.g., oral typhoid) given within 4 weeks: may diminish immune response to either vaccine. Moderate Interactions (Monitor Closely): - Immunoglobulins or blood products: may interfere with antibody formation if administered within 3 days before or after vaccination. - Immunosuppressive therapy: can reduce the immunogenicity of Menjugate. - Antipyretics (e.g., acetaminophen): may mask fever but generally do not affect vaccine efficacy. - Other vaccines administered simultaneously: monitor for additive local reactions.